2025-08-29 02:45:55
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Glenmark Life Sciences Ltd Q3 FY2022-23 PAT slips to Rs. 104.99 crores
Posted On : 2023-01-27 13:31:15( TIMEZONE : IST )
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 547.339 crores during the period ended December 31, 2022 as compared to Rs. 519.319 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 104.993 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 106.878 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 8.57 for the period ended December 31, 2022 as compared to Rs. 8.72 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹547.339 crs | ₹519.319 crs |  5.40% |
| Net Profit | ₹104.993 crs | ₹106.878 crs |  -1.76% |
| EPS | ₹8.57 | ₹8.72 | -1.72% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.547.339 crores during the period ended December 31, 2022 as compared to Rs.526.033 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.104.993 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.103.713 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.8.57 for the period ended December 31, 2022 as compared to Rs.8.65 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹547.339 crs | ₹526.033 crs | 4.05% |
| Net Profit | ₹104.993 crs | ₹103.713 crs | 1.23% |
| EPS | ₹8.57 | ₹8.65 | -0.92% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.1566.021 crores during the 9 Months period ended December 31, 2022 as compared to Rs.1618.766 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.320.604 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.319.827 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.26.16 for the 9 Months period ended December 31, 2022 as compared to Rs.27.60 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹1566.021 crs | ₹1618.766 crs | -3.26% |
| Net Profit | ₹320.604 crs | ₹319.827 crs | 0.24% |
| EPS | ₹26.16 | ₹27.60 | -5.22% |
Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 389.95 as compared to the previous close of Rs. 391.45. The total number of shares traded during the day was 7284 in over 1028 trades.
The stock hit an intraday high of Rs. 395.00 and intraday low of 386.20. The net turnover during the day was Rs. 2846013.00.
